about
Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasionSulodexide and glycosaminoglycans in the progression of renal diseaseImpact of heparanase on renal fibrosisDownregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patientsThe Story of SPATA2 (Spermatogenesis-Associated Protein 2): From Sertoli Cells to Pancreatic Beta-CellsNLRP3 inflammasome activation in dialyzed chronic kidney disease patients.Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.Recent data concerning heparanase: focus on fibrosis, inflammation and cancer.Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury.Heparanase as a target in cancer therapy.mTOR inhibitors and renal allograft: Yin and Yang.Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects.Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells.Heparanase is a key player in renal fibrosis by regulating TGF-β expression and activity.Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition.Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.Dialysis-related transcriptomic profiling: the pivotal role of heparanase.Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells.Antidepressant hyperforin up-regulates VEGF in CNS tumour cells.Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation.Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells.Involvement of heparanase in the pathogenesis of acute kidney injury: nephroprotective effect of PG545.Expression of LGI1 Impairs Proliferation and Survival of HeLa Cells.Heparanase and macrophage interplay in the onset of liver fibrosis.Heparanase regulates the M1 polarization of renal macrophages and their crosstalk with renal epithelial tubular cells after ischemia/reperfusion injury.In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets.Heparanase: another renal player controlled by vitamin DFluoxetine may worsen hyperoxia-induced lung damage in neonatal ratsL-citrulline Prevents Alveolar and Vascular Derangement in a Rat Model of Moderate Hyperoxia-induced Lung InjuryHeparanase: A Multitasking Protein Involved in Extracellular Matrix (ECM) Remodeling and Intracellular EventsCollagen Fiber Array of Peritumoral Stroma Influences Epithelial-to-Mesenchymal Transition and Invasive Potential of Mammary Cancer Cells
P50
Q21093315-82FD484A-6A46-45CF-80B6-020504EDBD60Q26991825-33CC9E43-55E4-4F1E-B0C8-294AFE873B8AQ28083753-61390790-7217-4ACC-828D-571AB738BF63Q28534658-0608FAF6-0B66-4286-88D5-AED31515ADFCQ33527928-2B0A91DE-5A5D-4F3F-99AB-1243CBBD6311Q35208558-117C79BE-44B6-4387-B0E9-56553E219C39Q35668839-DFFE6D1C-4133-4158-ABFA-A247DE4F14DEQ35775057-0975F316-47A4-4DD6-A8AD-56A7A91B2FA1Q35836200-A90CFB11-276F-4E3F-9CE9-95E9C0AD957CQ36088435-ED6BFC85-1E39-4767-B6DD-54C7DC224E87Q38190997-58035AAE-6320-4AA2-843F-C9CEE617E011Q38209973-29CE9723-B578-4029-A5F9-E1C1A8701B5BQ38220834-74CC2E81-E691-4EF5-BBCD-49822CD361FEQ38866153-FF68CE5D-F29A-45B9-A996-348BEDA338EDQ38983916-C8700758-6B31-47ED-8907-271EC50FEBAEQ39033979-4CDC719C-5877-4E86-9D38-43581A15FC0DQ39060681-FC4E0C12-437B-4592-8424-661DC6BED1CBQ39254044-34136C2C-4045-4D39-9CC3-D9A9E3417842Q39321185-ACA30161-BB45-482E-AE26-BA35530274DDQ39538883-4847EE4B-B33F-4B38-8EBF-73637CF45918Q39649544-1F579329-E020-4302-AED6-1D383D26D0C5Q39879207-EA8A051C-E1D4-4F40-BA80-ED3ABFA9B980Q40308327-2D5D1A92-FB63-4D51-9600-D705CB30F8F7Q41855773-ABDC366B-CBE2-435E-9C93-D24201F92B30Q42138210-C1A23536-4556-4B34-9F92-9E155FC435F8Q43812376-A50CCFA8-3AD2-4C9A-B57D-726991E20E1DQ50262560-120A44B2-D323-4690-8457-2A2062FA8805Q52314292-A5E6AF27-1380-4331-A245-5FA0770AC62AQ60904662-FAF0BFA3-EC93-46BE-97C4-E4095B83A924Q60904756-381CF6FF-0531-4888-83C7-C6728DF85253Q60904767-DAB0EADF-A6CE-406C-97A9-75840735418EQ60931211-A22DC64A-3469-4286-A0B6-B8F2DC3DA65AQ64243069-D51F0863-605D-4E1B-A66B-B9589A3AC454
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Valentina Masola
@ast
Valentina Masola
@en
Valentina Masola
@es
Valentina Masola
@fr
Valentina Masola
@nl
Valentina Masola
@sl
type
label
Valentina Masola
@ast
Valentina Masola
@en
Valentina Masola
@es
Valentina Masola
@fr
Valentina Masola
@nl
Valentina Masola
@sl
prefLabel
Valentina Masola
@ast
Valentina Masola
@en
Valentina Masola
@es
Valentina Masola
@fr
Valentina Masola
@nl
Valentina Masola
@sl
P214
P106
P21
P214
P31
P396
IT\ICCU\CFIV\269788
P496
0000-0003-2341-2481
P569
1982-01-01T00:00:00Z
P735
P7859
viaf-307342797